HOME >> MEDICINE >> NEWS
National Clinical Trial To Test Effectiveness Of Antibiotic Treatment For Coronary Artery Disease

Can heart disease -- the nation's number-one killer -- be effectively treated with antibiotics? A national clinical trial directed by the University of Washington and funded through an $11 million grant from the National Institutes of Health (National Heart, Lung and Blood Institute) and Pfizer Corporation will examine the effectiveness of antibiotic treatment for patients with coronary artery disease.

The Azithromycin and Cardiac Events Study (ACES) focuses on the role of a common bacterium, Chlamydia pneumoniae, that has been associated with atherosclerosis in humans. The study will be led by principal investigator

Dr. J. Thomas Grayston, a pioneer in chlamydia research and professor of epidemiology at the University of Washington School of Public Health and Community Medicine. Approximately 27 clinical centers nationwide will participate in the study.

"The idea of giving antibiotics to treat a chronic disease like coronary artery disease is not as farfetched an idea as it once was," said Grayston. "This clinical trial should help prove whether the Chlamydia pneumoniae bacteria plays a role in the cause of complications of atherosclerosis."

Chlamydia pneumoniae is a common cause of respiratory infections, including pneumonia and bronchitis. Nearly every person is infected with the bacteria at some time in life. In the late 1980s, researchers, including Grayston, identified a possible relationship between Chlamydia pneumoniae and heart disease when the bacteria was identified in samples of diseased coronary artery tissue.

Two small trials evaluating the use of antibiotics for patients with coronary artery disease showed some positive indications.

"This large-scale clinical trial will provide substantial evidence about whether antibiotics should be used in the treatment of coronary artery disease," Grayston said.

Participating research centers will enro
'"/>

Contact: Julie Rathbun
rath@u.washington.edu
206-543-3620
University of Washington
16-Nov-1998


Page: 1 2

Related medicine news :

1. National Academies advisory: May 2 Symposium on International Science Policy
2. National Academies News: William H. Foege to receive Public Welfare Medal, Academys highest honor
3. National Academies news: Academy honors 17 for major contributions to science
4. National Academies advisory: Report assesses health implications of perchlorate exposure
5. National Academies Advisory: Jan. 11 public briefing on perchlorate in drinking water
6. National Academies news: Gulf War and Health
7. National survey shows few physicians elected to Congress
8. Six new Roybal Centers for Applied Gerontology established by National Institute on Aging
9. UGA professor receives $3 million grant from National Cancer Institute for breast cancer research
10. National Academies advisory: Nov. 4-6 Frontiers of Science meeting in Irvine, Calif.
11. National Chemistry Week celebrates health and wellness in Washington, D.C., area

Post Your Comments:
(Date:7/25/2014)... July 25, 2014 Splashtop, Inc. announced ... Program . Splashtop Business and Splashtop Enterprise will now ... will leverage the MaaS360 WorkPlace SDK to enable enterprise-grade ... Business and Splashtop Enterprise offer secure remote access, support, ... High performance, ease of use, collaborative features, and ...
(Date:7/25/2014)... 2014 Training Mask LLC, is proud ... an endorsement agreement to promote the mask and its’ ... for over 10 years, and ran over 30 ultra ... of the Angeles Crest 100-mile endurance run. Brian is ... of the endurance, strength and conditioning paradigm. He created ...
(Date:7/25/2014)... An alpha olefin is an olefin or an ... alpha position of the carbon chain, or between the 1st ... namely, branched and linear (or normal). The alpha olefin market ... its applications such as polyethylene co-monomers and synthetic lubricants, across ... Europe have been lucrative markets for alpha olefins; however, Asia-Pacific ...
(Date:7/25/2014)... -- The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) ... Patent Pool (MPP) and Gilead Sciences, Inc. to ... promising new HIV medication. The agreement was announced ... in Melbourne, Australia. , While TAF is ... suggests it could be a key ingredient in ...
(Date:7/25/2014)... 2014 Ross A. Clevens, MD, FACS, ... to join the exclusive Obagi Clinical Advisory Board, comprised ... surgeons, plastic surgeons and dermatologists. , Dr. Clevens ... Board of thought leaders held its first meeting in ... to give Obagi the opportunity to meet with eight ...
Breaking Medicine News(10 mins):Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 2Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 3Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 4Health News:Training Mask LLC Announces the Signing of World-Renowned Coach Brian MacKenzie 2Health News:Training Mask LLC Announces the Signing of World-Renowned Coach Brian MacKenzie 3Health News:Europe Alpha Olefins Market is Expected to Reach $1,958 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Alpha Olefins Market is Expected to Reach $1,958 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Renowned Melbourne Plastic Surgeon to Join Private Medical Advisory Board 2
(Date:7/24/2014)... July 24, 2014  Kinex Pharmaceuticals announced the receipt ... Company,s KX2-391 Ointment for the commencement of a Phase ... Company,s third IND to be allowed by the US ... is a synthetic, orally active and highly selective inhibitor ... promotes the induction of p53, G2/M arrest of proliferating ...
(Date:7/24/2014)...  The American Association for Homecare (AAHomecare) yesterday ... help address audit issues in the HME industry ... the information technology lead in shaping its HME ... billing and business management solutions for nearly 3,000 ... support this important initiative on behalf of all ...
(Date:7/24/2014)... Research and Markets  has announced the ... Product, Component, Application and Geography - Global Forecast to ... http://photos.prnewswire.com/prnh/20130307/600769 ... a moderate growth as the markets of the U.S. ... the saturation levels. The demand is expected to come ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2
Cached News: